The utility of serum neutrophil gelatinase-associated lipocalin level on predicting autosomal dominant polycystic kidney disease progression.
hypertension
neutrophil gelatinase‐associated lipocalin
polycystic kidney disease
prognosis
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
revised:
26
02
2024
received:
22
11
2023
accepted:
08
05
2024
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
22
5
2024
Statut:
aheadofprint
Résumé
We focused on neutrophil gelatinase-associated lipocalin (NGAL) and autosomal dominant polycystic kidney disease (ADPKD) progression. ADPKD patients with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m Sixty one patients were enrolled and initial eGFR was 73.6 (48.9-101.5) ml/min/1.73m Relatively lower serum NGAL levels can predict worse outcomes in ADPKD and can provide risk stratification in patients with ADPKD.
Identifiants
pubmed: 38773764
doi: 10.1111/1744-9987.14163
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 International Society for Apheresis and Japanese Society for Apheresis.
Références
Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med. 1993;329(5):332–342.
Menezes LF, Germino GG. Systems biology of polycystic kidney disease: a critical review. Wiley Interdiscip Rev Syst Biol Med. 2015;7(1):39–52.
Li X. Epigenetics in ADPKD: understanding mechanisms and discovering treatment. In: Li X, editor. Polycystic kidney disease. Brisbane, Australia: Codon Publications; 2015. p. 283–311.
Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2007;2(1):112–120.
Chapman AB, Bost JE, Torres VE, Guay‐Woodford L, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7(3):479–486.
Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase‐associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534–2543.
Singer E, Markó L, Paragas N, Barasch J, Dragun D, Müller DN, et al. Neutrophil gelatinase‐associated lipocalin: pathophysiology and clinical applications. Acta Physiol. 2013;207(4):663–672.
Outcomes KDIG. Chapter 2: definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63–72.
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–172.
Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, et al. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012;81(8):784–790.
Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick‐Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal‐dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;28(2):380–385.
Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, et al. Neutrophil gelatinase‐associated lipocalin in patients with autosomal‐dominant polycystic kidney disease. Am J Nephrol. 2007;27(4):373–378.
Duan S, Chen J, Wu L, Nie G, Sun L, Zhang C, et al. Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease. J Diabetes Complicat. 2020;34(10):107665.
Patel ML, Sachan R, Misra R, Kamal R, Shyam R, Sachan P. Prognostic significance of urinary NGAL in chronic kidney disease. Int J Nephrol Renov Dis. 2015;8:139–144.
Seibert FS, Sitz M, Passfall J, Haesner M, Laschinski P, Buhl M, et al. Prognostic value of urinary calprotectin, NGAL and KIM‐1 in chronic kidney disease. Kidney Blood Press Res. 2018;43(4):1255–1262.
Romejko K, Markowska M, Niemczyk S. The review of current knowledge on neutrophil gelatinase‐associated Lipocalin (NGAL). Int J Mol Sci. 2023;24(13):10470.
Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil‐gelatinase‐associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005;579(3):773–777.
de Andrade LGM, Barbosa AMP, da Rocha NC, de Almeida Cardoso MM, de Almeida JTC, Machado‐Rugolo J, et al. Impact of the COVID‐19 pandemic on solid organ transplant and rejection episodes in Brazil's unified healthcare system. J Clin Med. 2022;11(21):6581.
Vareesangthip K, Vareesangthip K, Limwongse C, Reesukumal K. Role of urinary neutrophil gelatinase–associated lipocalin for predicting the severity of renal functions in patients with autosomal‐dominant polycystic kidney disease. Transplant Proc. 2017;49(5):950–954.
Virzì GM, Gastaldon F, Corradi V, de Cal M, Cruz DN, Clementi M, et al. Plasma NGAL and ADPKD progression. G Ital Nefrol. 2015;32(3):8.
Tsingos M, Merlini L, Solcà M, Goischke A, Wilhelm‐Bals A, Parvex P. Early urinary biomarkers in pediatric autosomal dominant polycystic kidney disease (ADPKD): No evidence in the interest of urinary neutrophil gelatinase‐associated Lipocalin (uNGAL). Front Pediatr. 2019;7:88.
Pana C, Stanigut AM, Cimpineanu B, Alexandru A, Salim C, Nicoara AD, et al. Urinary biomarkers in monitoring the progression and treatment of autosomal dominant polycystic kidney disease—the promised land? Medicina. 2023;59(5):915.
Chuang HY, Jeng WY. Secreted neutrophil gelatinase‐associated lipocalin shows stronger ability to inhibit cyst enlargement of ADPKD cells compared with nonsecreted form. Cells. 2022;11:3.